DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma
|ClinicalTrials.gov Identifier: NCT01419509|
Recruitment Status : Completed
First Posted : August 18, 2011
Last Update Posted : May 17, 2016
RATIONALE: DNA analysis of tumor, blood, and bone marrow may help doctors predict if the disease has been disseminated.
PURPOSE: This research trial studies DNA tests in detecting disseminated disease in tumor, blood, and bone marrow samples from patients with rhabdomyosarcoma.
|Condition or disease||Intervention/treatment|
|Sarcoma||Genetic: DNA methylation analysis Genetic: microarray analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis|
- To establish a panel of hypermethylation assays for minimal disseminated disease analysis in rhabdomyosarcoma (RMS).
- To apply the hypermethylation assays to a series of bone marrow specimens from RMS patients.
OUTLINE: Archived tumor, bone marrow, and peripheral blood samples are analyzed for DNA hypermethylation by PCR-based assays and microarray assays. Results are then compared with each patient's clinical and pathological characteristics, and outcomes. Patterns of locus hypermethylation in tumor and paired bone marrow samples are also compared.
|Study Type :||Observational|
|Estimated Enrollment :||170 participants|
|Official Title:||DNA Methylation-based Assays for Detecting Disease Spread in Rhabdomyosarcoma|
|Study Start Date :||August 2011|
|Primary Completion Date :||May 2016|
|Study Completion Date :||May 2016|
- Panel of hypermethylation assays for minimal disseminated RMS
- Detection of RMS cells in bone marrow
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01419509
|Principal Investigator:||Stephen R. Master, MD||University of Pennsylvania|